New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export MRNA’s income statement to Excel — free account
Moderna, Inc.
MRNAModerna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024.
- Revenue
- +29.2%
- EPS
- n/m
- Free cash flow
- n/m
- Total debt
- +13,550.0%
Quarter to September 2026, against a year earlier
195.12
4.21
−2.11%
After hours trading: 199.30, up 2.14%, last trade Fri 7:57pm Eastern.
Follow MRNA
Alert me
Revenue to profit Q3 FY2026, quarter to Sep 30, 2026
Of every $100 of revenue, $12.34 was left as profit. Gross margin has risen two quarters running, from −145.5% to 75.8%. What is an income statement?
| Revenue | 1.3 | 100.0% |
|---|---|---|
| Cost of revenue | −0.3 | −24.2% |
| Gross profit | 1.0 | 75.8% |
| Research & development | −0.6 | −44.4% |
| Selling, general & admin | −0.3 | −21.5% |
| Operating income | 0.1 | 9.9% |
| Other income, net | 0.0 | 3.1% |
| Income tax | 0.0 | −0.7% |
| Net income | 0.2 | 12.3% |
Net margin (right axis)
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Revenue | $678M | $389M | $145M | $1.3B |
| Operating income | −$857M | −$1.4B | −$815M | $130M |
| Net income | −$826M | −$1.3B | −$782M | $162M |
| Net margin (right axis) | −121.8% | −345.2% | −539.3% | 12.3% |
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Revenue |
1,313.00 | 145.00 | 389.00 | 678.00 |
+8 more quarters Free account |
Revenue Growth |
29.23% | 2.11% | 260.19% | (29.81%) | |
Cost of Revenue |
318.00 | 93.00 | 955.00 | 452.00 | |
Gross Profit |
995.00 | 52.00 | (566.00) | 226.00 | |
R&D Expenses |
583.00 | 651.00 | 649.00 | 775.00 | |
SG&A Expenses |
282.00 | 216.00 | 173.00 | 308.00 | |
Operating Income |
130.00 | (815.00) | (1,388.00) | (857.00) | |
Non-operating Income/Expense |
41.00 | 48.00 | 54.00 | 58.00 | |
| 171.00 | (767.00) | (1,334.00) | (799.00) | ||
Income Tax Provision |
9.00 | 15.00 | 9.00 | 27.00 | |
Income after Tax |
162.00 | (782.00) | (1,343.00) | (826.00) | |
Net Income Common |
162.00 | (782.00) | (1,343.00) | (826.00) | |
EPS (Basic) |
0.40 | (1.97) | (3.40) | (2.11) | |
EPS (Diluted) |
0.38 | (1.97) | (3.40) | (2.11) | |
Shares (Basic, Weighted) |
401.00 | 398.00 | 395.00 | 389.00 | |
Shares (Diluted, Weighted) |
430.00 | 398.00 | 395.00 | 389.00 | |
Gross Margin |
75.78% | 35.86% | (145.50%) | 33.33% | |
EBIT Margin |
9.90% | (562.07%) | (356.81%) | (126.40%) | |
EBT margin |
13.02% | (528.97%) | (342.93%) | (117.85%) | |
Net Profit Margin |
12.34% | (539.31%) | (345.24%) | (121.83%) | |
EBITDA |
186.00 | (762.00) | (1,340.00) | (803.00) | |
EBIT |
130.00 | (815.00) | (1,388.00) | (857.00) | |
Income from Continuous Operations |
162.00 | (782.00) | (1,343.00) | (826.00) | |
Consolidated Net Income/Loss |
162.00 | (782.00) | (1,343.00) | (826.00) | |
EPS (Basic, from Continuous Ops) |
0.40 | (1.96) | (3.40) | (2.10) | |
EPS (Diluted, from Cont. Ops) |
0.38 | (1.96) | (3.40) | (2.10) | |
EPS (Basic, Consolidated) |
0.40 | (1.96) | (3.40) | (2.10) | |
EPS (Diluted, Consolidated) |
0.38 | (1.96) | (3.40) | (2.10) | |
Shares (Diluted, Average) |
430.00 | 398.00 | 395.00 | 392.00 | |
EBITDA Margin |
14.17% | (525.52%) | (344.47%) | (118.44%) | |
Operating Cash Flow Margin |
(118.74%) | (362.76%) | (161.95%) | 137.17% |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 11, 2026